Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease
File(s)Letter C to Lancet GH v4.docx (39.15 KB)
Accepted version
Author(s)
Alexander, James
Selinger, Christian P
Powell, Nicholas
Type
Journal Article
Date Issued
2021-12
Date Acceptance
2021-10-05
Citation
The Lancet Gastroenterology & Hepatology, 2021, 6 (12), pp.987-988
ISSN
2468-1253
Publisher
Elsevier
Start Page
987
End Page
988
Journal / Book Title
The Lancet Gastroenterology & Hepatology
Volume
6
Issue
12
Copyright Statement
© 2021 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
Pfizer Limited
Identifier
https://www.sciencedirect.com/science/article/pii/S2468125321003745?via%3Dihub
Grant Number
66798527
Subjects
Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
POLYSACCHARIDE
Adolescent
Adult
Aged
Aged, 80 and over
COVID-19
COVID-19 Vaccines
Child
Humans
Immunization Schedule
Immunization, Secondary
Immunocompromised Host
Immunosuppressive Agents
Inflammatory Bowel Diseases
Middle Aged
Practice Guidelines as Topic
United Kingdom
Young Adult
British Society of Gastroenterology Inflammatory Bowel Disease section and the Inflammatory Bowel Disease Clinical Research Group
Humans
Inflammatory Bowel Diseases
Immunosuppressive Agents
Immunization Schedule
Immunization, Secondary
Immunocompromised Host
Adolescent
Adult
Aged
Aged, 80 and over
Middle Aged
Child
Practice Guidelines as Topic
Young Adult
United Kingdom
COVID-19
COVID-19 Vaccines
Publication Status
Published
Date Publish Online
2021-10-13